retinol-palmitate and Hypertension

retinol-palmitate has been researched along with Hypertension* in 1 studies

Other Studies

1 other study(ies) available for retinol-palmitate and Hypertension

ArticleYear
Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:2

    Dyslipidemia is common among patients receiving antiretroviral therapy for HIV infection. The purpose of this study was to determine whether postprandial lipemia contributes to the dyslipidemia observed in HIV-positive patients taking antiretroviral therapy.. A standardized fat load was administered to 65 subjects (group 1 35 HIV-positive subjects receiving protease inhibitors [PIs]; group 2 20 HIV-positive subjects not receiving PIs; group 3 10 HIV-negative controls). Serum triglycerides, retinyl palmitate, and lipoproteins were measured using enzymatic and nuclear magnetic resonance spectroscopic techniques. Compared with HIV-negative controls, peak postprandial retinyl palmitate and large very low-density lipoprotein (VLDL) levels occurred later in both HIV-positive groups, and a delayed decrease in serum triglycerides was observed. However, postprandial areas under the curve (AUCs) for triglycerides, retinyl palmitate, chylomicrons, and large VLDL were similar. Postprandial AUCs for intermediate-density lipoproteins (IDLs) and low-density lipoproteins (LDLs) were higher in group 1 than groups 2 and 3 (all P<0.035).. Postprandial clearance of triglyceride-rich lipoproteins is delayed in HIV-positive individuals receiving antiretroviral therapy. Compared with HIV-positive individuals not on PIs, those taking PIs do not have increased postprandial triglyceride-rich lipoproteins but do have increased postprandial IDLs and LDLs. An oral fat load was administered to 55 HIV-positive and 10 HIV-negative individuals. Postprandial clearance of triglyceride-rich lipoproteins was delayed in HIV-positive individuals. Compared with HIV-positive subjects not on PIs, those taking PIs do not have increased postprandial triglyceride-rich lipoproteins but do have increased postprandial intermediate-density and low-density lipoproteins.

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apolipoproteins E; Area Under Curve; Blood Glucose; Chylomicrons; Coronary Disease; Dietary Fats; Diterpenes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Hypertension; Insulin; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Postprandial Period; Retinyl Esters; Risk Factors; Smoking; Triglycerides; Vitamin A

2005